Skip to content

Transvaginal Ultrasound Cervical Length Screening in Singleton Pregnancy Without Prior Spontaneous Preterm Birth

Transvaginal Ultrasound Cervical Length Screening in Singleton Pregnancy Without Prior Spontaneous Preterm Birth

Status
Withdrawn
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02928302
Enrollment
0
Registered
2016-10-10
Start date
2018-07-23
Completion date
2020-12-31
Last updated
2018-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preterm Birth

Brief summary

Preterm birth (PTB) is a major cause of perinatal morbidity and mortality. Worldwide, about 15 million babies are born too soon every year, causing 1.1 million deaths, as well as short- and long-term disability in countless survivors. Few prognostic tests are available to predict PTB. A short transvaginal ultrasound cervical length (TVU CL) has been shown to be a good predictor of PTB.Different strategies have been adopted for prevention of PTB. The evidence supports the use of vaginal progesterone in singleton pregnancies with short cervix, while cervical cerclage seems to be beneficial only in the subgroup of singleton gestations with both prior spontaneous PTB and TVU CL ≤25mm, and not in singletons without prior PTB, nor in multiple gestations. However, so far there are no level-1 data on the efficacy of TVU CL screening neither in low risk nor in high risk pregnancy Thus, we aim to assess the efficacy of a policy of TVU CL screening in singleton pregnancy without prior spontaneous PTB

Interventions

OTHERTVU CL screening

Transvaginal ultrasound cervical length screening

Sponsors

Federico II University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* 18-50 years of age * Singleton pregnancy (limits the participants to female gender) * No prior spontaneous preterm delivery, defined as spontaneous preterm delivery 16 0/7 - 36 6/7 weeks

Exclusion criteria

* Multiple gestation * Prior spontaneous preterm birth 16-36 6/7 weeks * Ruptured membranes at time of randomization * Lethal fetal structural anomaly at time of randomization * Fetal chromosomal abnormality at time of randomization * Placenta previa and/or accreta at time of randomization * Women who already underwent TVU CL measurement during the index pregnancy

Design outcomes

Primary

MeasureTime frameDescription
preterm birth rateLess than 37 weekseither spontaneous or indicated preterm delivery

Secondary

MeasureTime frameDescription
preterm birth ratesLess than 24, 28, 32, 30, and 34 weeks gestationeither spontaneous or indicated preterm delivery
admission to neonatal intensive care unittime of delivery
Composite perinatal outcomeBetween birth and 28 days of ageIncludes necrotizing enterocolitis (NEC), intraventricular hemorrhage (IVH) (grade 3 or higher), respiratory distress syndrome (RDS), bronchopulmonary dysplasia (BPD), retinopathy (ROP), blood-culture proven sepsis and neonatal death
necrotizing enterocolitisBetween birth and 28 days of ageDefined as modified Bell Stage 2 or 3. Stage 2: Clinical signs and symptoms with pneumatosis intestinalis on radiographs. Stage 3: Advanced clinical signs and symptoms, pneumatosis, impending or proven intestinal perforation
intraventricular hemorrhage (grade 3 or higher)Between birth and 28 days of ageIVH
Perinatal deathBetween birth and 28 days of ageeither neonatal death or fetal death
birth weighttime of delivery
Length of hospital stayDischarge from hospitalDays in NICU
Neonatal deathBetween birth and 28 days of age
gestational age at deliverytime of delivery
latencytime of deliveryfrom randomization to delivery
respiratory distress syndromeTime of deliveryRespiratory distress with an oxygen requirement and a chest x-ray that shows hypoaeration and reticulogranular infiltrates

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026